Laboratory Corp. of America Holdings (LH) : Bridger Management reduced its stake in Laboratory Corp. of America Holdings by 17.68% during the most recent quarter end. The investment management company now holds a total of 663,004 shares of Laboratory Corp. of America Holdings which is valued at $92,853,710 after selling 142,388 shares in Laboratory Corp. of America Holdings , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Laboratory Corp. of America Holdings makes up approximately 5.60% of Bridger Management’s portfolio.
Other Hedge Funds, Including , Hbk Investments L P added LH to its portfolio by purchasing 3,371 company shares during the most recent quarter which is valued at $472,109. Laboratory Corp. of America Holdings makes up approx 0.01% of Hbk Investments L P’s portfolio.Fiduciary Financial Services Of The Southwest Inc Tx reduced its stake in LH by selling 125 shares or 5.19% in the most recent quarter. The Hedge Fund company now holds 2,285 shares of LH which is valued at $320,014. Laboratory Corp. of America Holdings makes up approx 0.10% of Fiduciary Financial Services Of The Southwest Inc Tx’s portfolio.Quantum Capital Management reduced its stake in LH by selling 5,640 shares or 4.24% in the most recent quarter. The Hedge Fund company now holds 127,284 shares of LH which is valued at $17,826,124. Laboratory Corp. of America Holdings makes up approx 2.41% of Quantum Capital Management’s portfolio.Fdo Partners boosted its stake in LH in the latest quarter, The investment management firm added 634 additional shares and now holds a total of 15,679 shares of Laboratory Corp. of America Holdings which is valued at $2,195,844. Laboratory Corp. of America Holdings makes up approx 1.13% of Fdo Partners’s portfolio.
Laboratory Corp. of America Holdings closed down -0.8 points or -0.58% at $136.13 with 4,65,523 shares getting traded on Thursday. Post opening the session at $136.93, the shares hit an intraday low of $135.5 and an intraday high of $137.14 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Laboratory Corp. of America Holdings reported $2.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.30. The company had revenue of $2382.00 million for the quarter, compared to analysts expectations of $2334.01 million. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.09 EPS.
Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing patient diagnosis and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment which includes core testing as well as genomic and esoteric testing; and the Other segment which consists of the Company’s non-United States clinical diagnostic laboratory operations in Ontario Canada. It also provides specialty testing services in the areas of allergy clinical trials diagnostic genetics women’s health cardiovascular disease identity forensics infectious disease endocrinology oncology coagulation occupational testing and pain management.